1. Differential expression of 37 selected genes in hormone-refractory prostate cancer using quantitative taqman real-time RT-PCR.
- Author
-
Fromont G, Chene L, Vidaud M, Vallancien G, Mangin P, Fournier G, Validire P, Latil A, and Cussenot O
- Subjects
- Androgens therapeutic use, DNA, Complementary, Genes, Tumor Suppressor, Humans, Lymph Node Excision, Male, Prognosis, Prostatectomy, RNA, Neoplasm genetics, RNA, Neoplasm isolation & purification, Receptors, Androgen genetics, Receptors, Cytoplasmic and Nuclear genetics, Signal Transduction, Androgens physiology, Gene Expression Regulation, Neoplastic genetics, Prostatic Neoplasms genetics, Reverse Transcriptase Polymerase Chain Reaction methods
- Abstract
Progression of prostate cancer to androgen independence remains the primary obstacle to improved survival. The development of more effective treatments depends on our understanding of the molecular events associated with the hormone-refractory stage. We quantified, among 90 screened genes, the expression of 37 target genes, using real-time quantitative RT-PCR. Gene expression was studied in 13 samples of HPRC compared to 33 clinically localised cancers and normal prostate tissue. We identify 19 genes with significant differential expression in HRPC compared to localised prostate cancer. Genes with decreased expression included receptors for growth factors, MMR genes and the serine protease hepsin. Analysis of increased gene expression confirmed the importance of AR upregulation and highlighted genes not previously linked to HRPC, including enzymes involved in steroid synthesis and the antiapoptotic factor survivin. Progression of prostate cancer to the hormone-refractory state is associated with differential gene expression, which may prove useful for both understanding disease progression and the development of new therapeutic approaches., ((c) 2004 Wiley-Liss, Inc.)
- Published
- 2005
- Full Text
- View/download PDF